These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8842613)

  • 1. Should we use intensive insulin therapy after oral agent failure in type II diabetes?
    Colwell JA
    Diabetes Care; 1996 Aug; 19(8):896-8. PubMed ID: 8842613
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetic complications. The importance of glucose control.
    Skyler JS
    Endocrinol Metab Clin North Am; 1996 Jun; 25(2):243-54. PubMed ID: 8799699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.
    Ohkubo Y; Kishikawa H; Araki E; Miyata T; Isami S; Motoyoshi S; Kojima Y; Furuyoshi N; Shichiri M
    Diabetes Res Clin Pract; 1995 May; 28(2):103-17. PubMed ID: 7587918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current unsolved problems in diabetes management.
    Fajans SS
    Diabetes; 1972; 21(2 Suppl):678-84. PubMed ID: 5054334
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
    Ismail-Beigi F; Craven T; Banerji MA; Basile J; Calles J; Cohen RM; Cuddihy R; Cushman WC; Genuth S; Grimm RH; Hamilton BP; Hoogwerf B; Karl D; Katz L; Krikorian A; O'Connor P; Pop-Busui R; Schubart U; Simmons D; Taylor H; Thomas A; Weiss D; Hramiak I;
    Lancet; 2010 Aug; 376(9739):419-30. PubMed ID: 20594588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.
    Emanuele N; Klein R; Abraira C; Colwell J; Comstock J; Henderson WG; Levin S; Nuttall F; Sawin C; Silbert C; Lee HS; Johnson-Nagel N
    Diabetes Care; 1996 Dec; 19(12):1375-81. PubMed ID: 8941467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DCCT: implications for diabetes care in the UK.
    Boulton AJ
    Diabet Med; 1993 Oct; 10(8):687. PubMed ID: 8261748
    [No Abstract]   [Full Text] [Related]  

  • 9. A summary of the ADVANCE Trial.
    Heller SR;
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S357-61. PubMed ID: 19875581
    [No Abstract]   [Full Text] [Related]  

  • 10. Diabetes specialists keep ACCORD data in perspective.
    Traynor K
    Am J Health Syst Pharm; 2008 Mar; 65(6):488, 490. PubMed ID: 18319488
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UKPDS and the legacy effect.
    Chalmers J; Cooper ME
    N Engl J Med; 2008 Oct; 359(15):1618-20. PubMed ID: 18843126
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of combination therapy in type 2 diabetes in the post-ACCORD era.
    Kuritzky L
    Curr Diab Rep; 2012 Jun; 12(3):227-9. PubMed ID: 22528598
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical review 51: Implications of the Diabetes Control and Complications Trial.
    Eastman RC; Siebert CW; Harris M; Gorden P
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1105-7. PubMed ID: 8077299
    [No Abstract]   [Full Text] [Related]  

  • 15. Early diabetic complications in a population of young patients with type 1 diabetes mellitus despite intensive treatment.
    Nordwall M; Hyllienmark L; Ludvigsson J
    J Pediatr Endocrinol Metab; 2006 Jan; 19(1):45-54. PubMed ID: 16509528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evidence based therapy with insulin in diabetic patients].
    Jermendy G
    Orv Hetil; 2005 Feb; 146(8):341-52. PubMed ID: 15803885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3: Preventing complications of diabetes.
    Bate KL; Jerums G
    Med J Aust; 2003 Nov; 179(9):498-503. PubMed ID: 14583083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose control and vascular complications in veterans with type 2 diabetes.
    Duckworth W; Abraira C; Moritz T; Reda D; Emanuele N; Reaven PD; Zieve FJ; Marks J; Davis SN; Hayward R; Warren SR; Goldman S; McCarren M; Vitek ME; Henderson WG; Huang GD;
    N Engl J Med; 2009 Jan; 360(2):129-39. PubMed ID: 19092145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes.
    Buysschaert M; Hermans MP
    Acta Clin Belg; 1999 Dec; 54(6):328-33. PubMed ID: 10686705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.